Shattuck Labs

STTK

Market cap $94.8M

1.98 USD

+0.02

1.02%

At close Updated Nov 7, 4:00 PM EST

Pre-market

After hours

1.92

--0.06

3.03%

1 day

1.02%

5 days

1.54%

1 month

-19.18%

3 months

153.55%

6 months

126.96%

Year to date

63.64%

1 year

59.68%

5 years

-91.56%

10 years

-89.77%

About: Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Employees: 44

Healthcare Biotechnology